Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Leslie Cho, MD, is Director of the Cleveland Clinic’s Women’s Cardiovascular Center. She is also Section Head, Preventive Cardiology and Rehabilitation in the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at Cleveland Clinic. Dr. Cho is board-certified in interventional cardiology, cardiovascular medicine, and internal medicine. Her specialty interests focus on general cardiology, heart disease, and peripheral arterial and vascular disease and their attendant therapies and treatments. Dr. Cho specializes in heart disease in women.
Dr. Cho received her undergraduate degree in interdisciplinary studies from the University of California, Los Angeles, graduating cum laude. She received her medical degree from the University of Chicago Pritzker School of Medicine, and took her residency in internal medicine at the University of Washington Medical Center where she received the John Humphrey Award as Most Outstanding Internal Medicine Resident. Her clinical training continued when she accepted a fellowship in cardiology, followed by a fellowship in interventional cardiology and peripheral disease, both from Cleveland Clinic.
Prior to her appointment to Cleveland Clinic in 2005 as Director of the Women’s Cardiovascular Center, Dr. Cho was Assistant Professor of Medicine, Section on Interventional Cardiology in the Division of Cardiology at Loyola University Medical Center, where she also served as both Director of Carotid Intervention and Director of Interventional Cardiology Research.
Dr. Cho’s clinical research interests are women and heart disease and the role of nutrition in hypercholesterolemia. Her research has garnered her many grants to study various therapeutic treatments for heart disease. In 1998, she received the American Heart Association’s Women in Cardiology award. In 1999, the World Heart Federation named her Fellow of Cardiovascular Epidemiology and Prevention.
She is author or co-author of numerous peer-reviewed articles and abstracts in leading medical journals, and she has authored medical textbooks and contributed chapters to medical textbooks related to her specialty interests.
Dr. Cho is a Fellow of the American College of Cardiology (FACC) and serves on the Peripheral Disease Committee. She is a member of the American Board of Internal Medicine and the American Heart Association.
Cardiovascular Disease, cardiovascular risk prevention, cardiac catheterization, coronary balloon angioplasty (PTCA), C-Reactive protein testing, high cholesterol, preventive cardiology, peripheral artery disease, women's cardiovascular disease
Awards & Honors
National Peripheral Disease Committee, American College of Cardiology, 2005-2008
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 5/19/2016, Dr. Cho has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.